Results
1 -
10 of
17Henke Brad R., Blanchard Steven G., Brackeen Marcus F., Brown Kathleen K., Cobb Jeff E., Collins Jon L., Harrington, W. Wallace, Hashim Mir A., Hull-Ryde Emily A., Kaldor Istvan, Kliewer Steven A., Lake Debra H., Leesnitzer Lisa M., Lehmann Jürgen M., Lenhard James M., Orband-Miller Lisa A., Miller John F., Mook, Robert A., Noble Stewart A., Oliver, William, Parks Derek J., Plunket Kelli D., Szewczyk Jerzy R., Willson Timothy M..
N-(2-Benzoylphenyl)-l-tyrosine PPARγ Agonists. 1. Discovery of a Novel Series of Potent Antihyperglycemic and Antihyperlipidemic Agents, Journal of Medicinal Chemistry, 1998 Design, Structure, and Function of Novel PPAR Ligands, Peroxisome Proliferator Activated Receptors: From Basic Science to Clinical Applications In silico Studies on PPAR?? Agonistic Heterocyclic Systems, QSAR and Molecular Modeling Studies in Heterocyclic Drugs I Chemical Genomics of Orphan Nuclear Receptors, Small Molecule u2014 Protein Interactions The application of comparative molecular field analysis for the design of ??-anilino substituted-3-phenyl propanoic acids as novel PPAR??/?? dual ligands, Medicinal Chemistry Research 3D QSAR studies on peroxisome proliferator-activated receptor ?? agonists using CoMFA and CoMSIA, Journal of Molecular Modeling Peroxisome Proliferator-Activated Receptors target family landscape: A chemometrical approach to ligand selectivity based on protein binding site analysis, Journal of Computer-Aided Molecular Design Rational drug design and PPAR Agonists, Current Diabetes Reports Design, synthesis and computational validation of novel benzimidazole/indole-based PPAR?? and PPAR?? partial agonists, Journal of Chemical Sciences